Haizheng Pharmaceutical (600267.SH): Tacrolimus capsules and four other products are proposed to be selected for centralized bulk procurement.

Zhuhai Finance APP reported that Haizheng Pharmaceutical (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd. (referred to as "Hanhui Pharmaceutical"), participated in the bidding for the twelfth batch of national centralized procurement organized by the Joint Procurement Office. According to the "Public Announcement of the Proposed Selected Results for the 12th Batch of National Centralized Procurement" released by the Joint Procurement Office that evening, the company and its wholly-owned subsidiary Hanhui Pharmaceutical have five products that meet the scope of this centralized procurement and are proposed to be selected for this centralized procurement.